Srushti Gandhi¹*, Rashid Merchant² and Snehal Mallakmir²

¹Department of Paediatrics, Nanavati Super Specialty Hospital, Mumbai, Maharashtra, India
²Department of Genetics, Nanavati Super Specialty Hospital, Mumbai, Maharashtra, India

*Corresponding Author: Srushti Gandhi, Department of Paediatrics, Nanavati Super Specialty Hospital, Mumbai, Maharashtra, India.

Received: March 04, 2022; Published: April 28, 2022

Abstract

Langerhans cell histiocytosis (LCH) is a rare clonal disease of the monocyte-macrophage system, comprising of uncontrolled proliferation of CD1a+/CD207+ dendritic cells (DCs). It has a wide range of symptomatology making early diagnosis and intervention extremely challenging. LCH may range from mild single system involvement with isolated skin or bone lesions to life-threatening multi-system involvement. Furthermore, when risk organs are involved, even with aggressive treatment, 10-year survival rates are only 50%, further emphasizing the need for maintaining a high index of suspicion and early intervention. We present the case of a 2-year-old girl who arrived at our clinic with a painless lump over the head following a trivial head injury, and on further evaluation was found to have histopathologically confirmed multisystemic LCH. Response to treatment has been favourable.

Keywords: Langerhans Cell Histiocytosis; CD1a+/CD207+; Monocyte-Macrophage System; Litterer Siwe Disease; Hand-Schüller-Christian Disease

References

1. Haupt R., et al. “Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patient till age of 18 years”. Pediatric Blood Cancer 60 (2013): 175-184. 
2. Emile JF., et al. “Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages”. Blood 127.22 (2016): 2672-2681. 
3. Minkov M. “Multisystem Langerhans cell histiocytosis in children. Current treatment and future directions”. Pediatric Drugs 13 (2011): 75-86. 
4. Margo CE and Goldman DR. “Langerhans cell histiocytosis”. Survey of Ophthalmology 53 (2008): 332-358. 
5. Grana N. “Langerhans cell histiocytosis”. Cancer Control 21 (2014): 328-334. 
6. Postini AM., et al. “Langerhans cell histiocytosis: 40 years’ experience”. Pediatric Hematology and Oncology 34 (2012): 353-358. 
7. Minkov M., et al. “Langerhans cell histiocytosis - Histiocyte Society Evaluation and Treatment Guidelines”. Protocol (2009)
8. Abla O., et al. “Langerhans cell histiocytosis: current concepts and treatments”. Cancer Treatment Reviews 36 (2010): 354-359. 
9. Donadieu J., et al. “Medical management of Langerhans cell histiocytosis from diagnosis to treatment”. Expert Opinion on Pharmacotherapy 13 (2012): 1309-1322. 
10. Windebank K and Naduri V. “Langerhans cell histiocytosis”. Archives of Disease in Childhood 94 (2009): 904-908.
11. Krooks J., et al. “Langerhans cell histiocytosis in children: diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up”. Journal of the American Academy of Dermatology 78.6 (2018): 1035-1044.
12. Gadner H., et al. “A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis”. The Journal of Pediatrics 138.5 (2001): 728-734.
13. Arkader A., et al. “Primary Musculoskeletal Langerhans Cell Histiocytosis in Children: An Analysis for a 3-Decade Period”. Journal of Pediatric Orthopaedics 29.2 (2009): 201-207.
14. Cochrane Central Register of Controlled Trials. “LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis” 5 (2018).

Citation

Citation: Srushti Gandhi., et al. “A Case Report of a Child with Langerhans Cell Histiocytosis". Acta Scientific Gastrointestinal Disorders 5.5 (2022): 31-36.

Copyright

Copyright: © 2022 Srushti Gandhi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.